Insulet Co. (NASDAQ:PODD) Stake Boosted by Shaker Investments LLC OH

Shaker Investments LLC OH lifted its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 83.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,234 shares of the medical instruments supplier's stock after buying an additional 9,222 shares during the period. Insulet accounts for approximately 2.2% of Shaker Investments LLC OH's holdings, making the stock its 10th biggest position. Shaker Investments LLC OH's holdings in Insulet were worth $5,282,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of PODD. Baillie Gifford & Co. boosted its holdings in shares of Insulet by 20.7% during the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock valued at $529,669,000 after acquiring an additional 389,639 shares during the period. Mizuho Securities USA LLC lifted its position in Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier's stock valued at $75,835,000 after purchasing an additional 320,416 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock valued at $148,091,000 after purchasing an additional 193,839 shares during the period. Westfield Capital Management Co. LP grew its position in Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock worth $175,697,000 after purchasing an additional 163,388 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec acquired a new stake in shares of Insulet in the third quarter valued at approximately $16,342,000.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PODD. Canaccord Genuity Group boosted their price objective on Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. TD Cowen increased their price target on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, January 3rd. Wells Fargo & Company lifted their price objective on shares of Insulet from $290.00 to $305.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 price objective for the company. Finally, Barclays raised their target price on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and a consensus target price of $277.13.

Insulet Trading Down 0.4 %

Shares of Insulet stock traded down $1.07 on Friday, reaching $281.06. 208,532 shares of the company were exchanged, compared to its average volume of 519,517. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The firm has a market capitalization of $19.71 billion, a price-to-earnings ratio of 48.13, a price-to-earnings-growth ratio of 3.61 and a beta of 1.23. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a fifty day moving average price of $271.44 and a 200-day moving average price of $243.41.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.